复方苦参注射液胸腔灌注治疗肺癌合并恶性胸腔积液的meta分析  

Meta analysis of compound Kushen injection for thoracic infusion treatment of lung cancer complicated with malignant pleural effusion

作　　者：蒋慧 邢晓燕 杨浩 臧建华 龙麟 方超 刘玮[1] 肖军 Jiang Hui;Xing Xiaoyan;Yang Hao;Zang Jianhua;Long Lin;Fang Chao;Liu Wei;Xiao Jun(Department of Oncology,Qingdao Haici Hospital Affiliated to Qingdao University,Qingdao 266000,China)

机构地区：[1]青岛大学附属青岛市海慈医院肿瘤一科,266000 [2]青岛大学附属青岛市海慈医院骨关节与创伤外科,266000

出　　处：《北京医学》2024年第12期1044-1050,1056,共8页Beijing Medical Journal

基　　金：青岛市医药卫生科研指导项目(2022-WJZD038);山东省中医药科技项目(2020Z31)。

摘　　要：目的 探讨复方苦参注射液(compound Kushen injection, CKI)胸腔灌注治疗肺癌合并恶性胸腔积液(malignant pleural effusion, MPE)的临床疗效和安全性。方法 选取建库至2023年8月15日中国知网、万方数据库、维普数据库、中国生物医学文献数据库等数据库公开发表的关于CKI在临床上治疗MPE的随机对照试验类文献,依次通过浏览标题、摘要和全文,以临床缓解度作为主要结局指标,以卡氏(Karnofsky performance status, KPS)评分及不良反应发生情况作为次要结局指标,分析CKI胸腔灌注治疗肺癌合并MPE的临床疗效和安全性。结果 共计检索文献347篇,最终纳入文献18篇,涉及1 228例患者,对照组与联合组各614例。Meta分析结果显示,联合组临床缓解度、KPS评分与不良反应发生情况(胸痛、胃肠道反应、骨髓抑制、肝肾功能损伤)均明显优于对照组(P<0.05)。结论 对于肺癌合并MPE患者,联用CKI胸腔灌注可以有效减少MPE程度,提高患者的生活质量,降低不良反应情况,值得临床推广。Objective To explore the clinical efficacy and safety of compound Kushen injection(CKI)in the treatment of lung cancer complicated with malignant pleural effusion(MPE)through thoracic perfusion.Methods Randomized controlled trials of CKI in the treatment of MPE in China National Knowledge Infrastructure,Wanfang Database,VIP Database and China Biomedical Literature Database from the databases published to August 15th,2023 were selected.The clinical efficacy and safety of CKI thoracic perfusion therapy for lung cancer with MPE were analyzed by browsing the titles,abstracts,and full texts,with clinical remission as the primary outcome measure and Karnofsky performance status(KPS)score and incidence of adverse reactions as secondary outcome measures.Results A total of 347 articles were retrieved,and 18 articles were ultimately included,involving 1228 patients,and 614 patients in the control group and 614 patients in the combination group.The meta-analysis results showed that the clinical remission,KPS score,and incidence of adverse reactions(chest pain,gastrointestinal reactions,bone marrow suppression,liver and kidney dysfunction)in the combination group were significantly better than those in the control group(P<0.05).Conclusions For patients with lung cancer complicated with MPE,the combination of CKI thoracic perfusion can effectively reduce the degree of MPE,improve the quality of life of patients,and reduce adverse reactions,which is worthy of clinical promotion.

关 键 词：复方苦参注射液 恶性胸腔积液 有效性 不良反应 生活质量 META分析 

分 类 号：R73[医药卫生—肿瘤]